CompletedPhase 2

Role of Neuraminidase Activity on Endothelial Dysfunction in Type 2 Diabetes

United States14 participantsStarted 2021-07-14

Plain-language summary

The objective is to determine if neuraminidase inhibition with zanamivir is efficacious as a therapeutic strategy to restore endothelial function in T2D patients.

Who can participate

Age range45 Years – 64 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Men and women with a BMI of 25-39 kg/m2
✓. Ages 45-64 years at randomization.
✓. Diagnosis of T2D classified based on physician diagnosis.
✓. No vulnerable populations (e.g., prisoners, pregnant, children) will be enrolled.

Exclusion criteria

✕. Cardiovascular disease including myocardial infraction, heart failure, coronary artery disease, stroke
✕. History of chronic renal or hepatic disease
✕. Active cancer
✕. Autoimmune diseases
✕. Immunosuppressant therapy
✕. Hormone replacement therapy
✕. Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
✕. Current tobacco use

What they're measuring

Change in Glycocalyx Integrity-Perfused Boundary Region

Timeframe: Day 0 and Day 5

Trial details

NCT IDNCT04867707

SponsorUniversity of Missouri-Columbia

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-10-18

Results submitted2025-04-01

View on ClinicalTrials.gov More Diabetes Mellitus, Type 2 trials